CR:DOI:c95f54188db7f1d73abce2f0fe54c15c
From IDWiki
{{#scite:
|reference=maertens2021po
|type=journal-article
|title=Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
|author=Johan A Maertens;Galia Rahav;Dong-Gun Lee;Alfredo Ponce-de-León;Isabel Cristina Ramírez Sánchez;Nikolay Klimko;Anne Sonet;Shariq Haider;Juan Diego Vélez;Issam Raad;Liang-Piu Koh;Meinolf Karthaus;Jianying Zhou;Ronen Ben-Ami;Mary R Motyl;Seongah Han;Anjana Grandhi;Hetty Waskin|+sep=;
|journal=The Lancet
|publisher=Elsevier BV
|year=2021
|volume=397
|issue=10273
|pages=499-509
|doi=10.1016/s0140-6736(21)00219-1
|issn=0140-6736
|retrieved-from=https://dx.doi.org/
|retrieved-on=2024-10-01
}}
